Maravai LifeSciences (MRVI) Competitors $2.22 -0.12 (-5.13%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 08/1/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. APLS, XENE, IBRX, BHC, AGIO, CNTA, BEAM, TWST, KNSA, and IRONShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Kiniksa Pharmaceuticals International (KNSA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors Apellis Pharmaceuticals Xenon Pharmaceuticals ImmunityBio Bausch Health Cos Agios Pharmaceuticals Centessa Pharmaceuticals Beam Therapeutics Twist Bioscience Kiniksa Pharmaceuticals International Disc Medicine Maravai LifeSciences (NASDAQ:MRVI) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Which has more volatility & risk, MRVI or APLS? Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Does the media refer more to MRVI or APLS? In the previous week, Apellis Pharmaceuticals had 29 more articles in the media than Maravai LifeSciences. MarketBeat recorded 36 mentions for Apellis Pharmaceuticals and 7 mentions for Maravai LifeSciences. Apellis Pharmaceuticals' average media sentiment score of 0.81 beat Maravai LifeSciences' score of 0.70 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is MRVI or APLS more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-67.14% -12.91% -6.87% Apellis Pharmaceuticals -30.24%-108.68%-26.39% Do institutionals & insiders believe in MRVI or APLS? 50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 2.1% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, MRVI or APLS? Maravai LifeSciences has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$259.18M2.18-$144.85M-$1.14-1.95Apellis Pharmaceuticals$781.37M3.69-$197.88M-$1.79-12.82 Do analysts prefer MRVI or APLS? Maravai LifeSciences presently has a consensus price target of $6.64, indicating a potential upside of 199.05%. Apellis Pharmaceuticals has a consensus price target of $37.78, indicating a potential upside of 64.61%. Given Maravai LifeSciences' higher probable upside, equities research analysts plainly believe Maravai LifeSciences is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.60 SummaryApellis Pharmaceuticals beats Maravai LifeSciences on 11 of the 17 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$595.90M$10.40B$5.49B$9.52BDividend YieldN/A1.99%4.73%4.09%P/E Ratio-1.9518.4228.7823.81Price / Sales2.1829.01372.2066.04Price / Cash3.7922.3135.4557.96Price / Book0.973.478.275.54Net Income-$144.85M$234.77M$3.25B$259.28M7 Day Performance-17.47%-4.82%-3.70%-4.64%1 Month Performance-16.23%1.80%4.34%4.41%1 Year Performance-76.31%-12.51%25.90%17.95% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.7585 of 5 stars$2.22-5.1%$6.64+199.0%-76.9%$595.90M$259.18M-1.95610Gap DownAPLSApellis Pharmaceuticals4.7035 of 5 stars$19.28-1.0%$40.00+107.5%-36.3%$2.42B$781.37M-10.77770Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals2.9466 of 5 stars$31.49-0.3%$54.82+74.1%-30.3%$2.42B$9.43M-9.75210News CoveragePositive NewsShort Interest ↑IBRXImmunityBio2.4115 of 5 stars$2.68-2.5%$12.25+357.1%-50.5%$2.37B$14.74M-4.62590News CoverageGap DownBHCBausch Health Cos4.6511 of 5 stars$6.34+0.4%$7.30+15.2%-6.4%$2.34B$9.63B-57.6020,700News CoverageEarnings ReportAnalyst UpgradeAGIOAgios Pharmaceuticals4.0146 of 5 stars$39.92-0.2%$58.60+46.8%-21.3%$2.31B$37.04M3.55390News CoverageEarnings ReportCNTACentessa Pharmaceuticals3.2055 of 5 stars$16.06+2.4%$28.10+75.0%+63.4%$2.14B$6.85M-8.87200News CoverageAnalyst ForecastInsider TradeBEAMBeam Therapeutics2.6099 of 5 stars$21.03+1.3%$48.75+131.8%-37.9%$2.11B$63.52M-4.56510Upcoming EarningsInsider TradeGap DownTWSTTwist Bioscience3.5578 of 5 stars$34.77-1.1%$50.40+45.0%-36.5%$2.08B$312.97M-10.70990News CoverageUpcoming EarningsShort Interest ↑Gap DownKNSAKiniksa Pharmaceuticals International3.1521 of 5 stars$28.42-2.1%$39.33+38.4%+24.1%$2.07B$423.24M-113.68220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionIRONDisc Medicine3.5418 of 5 stars$59.38+2.8%$95.73+61.2%+36.3%$2.06BN/A-15.1530Positive NewsUpcoming EarningsInsider Trade Related Companies and Tools Related Companies APLS Alternatives XENE Alternatives IBRX Alternatives BHC Alternatives AGIO Alternatives CNTA Alternatives BEAM Alternatives TWST Alternatives KNSA Alternatives IRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRVI Stock Alerts